Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23592 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL147956 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL6679408 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL8747818 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL8619595 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL123336 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL22782 | 0.91 | — | — | |
| SCHEMBL1445922 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL9492690 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 | |
| SCHEMBL9838508 | 0.91 | CA4 (0.36) | CA4CA1FAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918746-B2 | Radioactive compositions and methods for their therapeutic use | ISOTHERAPEUTICS GROUP LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200155716-A1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | ISOTHERAPEUTICS GROUP LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10583211-B2 | Radioactive compositions and methods for their therapeutic use | ISOTHERAPEUTICS GROUP LLC (US) | 2020-03-10 | — | — | US | disclosed |
| CN-110589870-A | Method for preparing monodisperse spherical nano rare earth oxide by uniform precipitation process | 桂林电子科技大学 | 2019-12-20 | — | — | CN | disclosed |
| EP-2793955-B1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | ISOTHERAPEUTICS GROUP LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170258949-A1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | ISOTHERAPEUTICS GROUP LLC (US) | 2017-09-14 | — | — | US | disclosed |
| CN-106967415-A | Method for influencing size of ferroferric oxide wrapped by lutetium sodium tetrafluoride by controlling size of nucleus | 南京工业大学 | 2017-07-21 | — | — | CN | disclosed |
| US-9687574-B2 | Radioactive compositions and methods for their therapeutic use | ISOTHERAPEUTICS GROUP LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150023869-A1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | ISOTHERAPEUTICS GROUP LLC (US) | 2015-01-22 | — | — | US | disclosed |
| EP-2793955-A2 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | ISO Therapeutics Group LLC (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096776-A2 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | ISO THERAPEUTICS GROUP LLC (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023869-A1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | SLC39A3, RO60, TP53 | CA4 272/4885CA1 178/4885FAHD1 802/4885 |
| US-10583211-B2 | Radioactive compositions and methods for their therapeutic use | SLC39A3, RO60, TP53 | CA4 272/4885CA1 178/4885FAHD1 802/4885 |
| US-20170258949-A1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | SLC39A3, RO60, TP53 | CA4 272/4885CA1 178/4885FAHD1 802/4885 |
| US-10918746-B2 | Radioactive compositions and methods for their therapeutic use | SLC39A3, RO60, TP53 | CA4 272/4885CA1 178/4885FAHD1 802/4885 |
| US-20200155716-A1 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE | SLC39A3, RO60, TP53 | CA4 272/4885CA1 178/4885FAHD1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.